Biogen Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 02:40PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst

Well, thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. We're very pleased to have Biogen. Joining us today from the company is Chris Viehbacher, CEO. Chris, thanks so much for being here.

Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Well, thanks so much, Chris. I really appreciate the time today. I know it's a busy time at Biogen.

Questions and Answers:

Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst

Maybe to start, I thought we could talk about what's some of your key priorities are over the next year?

Christopher A. Viehbacher - Biogen Inc. - President, CEO & Director

Yes. Thanks, Terence. It has been a busy, I think it's 8 months, maybe 9 months now. I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot